- Home
- Evidence Based Probiotics
- Yomogi® Saccharomyces cerevisiae Boulardii HANSEN CBS 5926 / CNCM I 745
Yomogi® Saccharomyces cerevisiae Boulardii HANSEN CBS 5926 / CNCM I 745
02 Question and Answers
- Description
- Ingredients
- Indications
- FAQ
- Availability
Yomogi® is presented in either a 20 or 50 capsule pack
Appearance – light green/yellow hard capsules
1 hard capsule contains:
At release – a minimum of 2.5 billion viable cells of Saccharomyces cerevisiae HANSEN CBS 5926 (synonym: Saccharomyces boulardii) in 250 mg lyophilisate.
At release – a minimum of 2.5 billion viable cells of Saccharomyces cerevisiae HANSEN CBS 5926 (synonym: Saccharomyces boulardii) in 250 mg lyophilisate.
A patient / consumer information leaflet accompanies every pack and contains important information relating to the safe use of this product and lists all excipients.
Download – Yomogi® Patient information Leaflet
Other ingredients
Lactose, magnesium stearate (Ph.Eur.), gelatin, water, sodium dodecyl sulfate, chlorophyllin-copper complex, titanium dioxide, iron oxide hydrate.
Yomogi® Saccharomyces cerevisiae (boulardii) is registered in Australia.
TGA AUST L : 321332
- For the relief and treatment of diarrhoea
- Helps to reduce and relieve diarrhoea after antibiotic use
- Helps reduce occurrence of diarrhoea
- Helps to reduce occurrence and relieve travellers’ diarrhoea
- May reduce the risk of diarrhoea when travelling
Dosage
Adults: 1 capsule 1-2 times daily
Children: 2-6 years of age, same dosage but the hard capsule is to be opened and contents stirred into food or liquid
Travellers’ diarrhoea: 1 capsule 1-2 times daily starting 5 days before departure and continue for the duration of travel.
If symptoms persist consult your healthcare practitioner.
If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children 3-6 years or 48 hours in adults and children over 6 years, seek medical advice.
Contains lactose. For diabetics, taking 1 hard Yomogi® capsule should be calculated as 0.01 carbohydrate exchange units.
Download – Yomogi® Patient Information Leaflet
- What is Yomogi®?...and what is it used for?
Yomogi® is a probiotic that comprises as its active substance 250 mg of lyophilized yeast cells that at batch release contains a minimum of 2.5 billion CFU (colony forming units) of a viable non-pathogenic cells of the yeast strain Saccharomyces cerevisiae (boulardii) HANSEN CBS 5926. Saccharomyces boulardii is indicated for the treatment of diarrhoea, often a symptom of gastrointestinal disorders. Saccharomyces boulardii is able to help and support a healthy microbial environment.
- Is Saccharomyces boulardii the same as Saccharomyces cerevisiae?
No, Saccharomyces boulardii is not Saccharomyces cerevisiae. Saccharomyces boulardii is a wild, tropical yeast while Saccharomyces cerevisiae, is commonly known as brewer’s or baker’s yeast. Whilst closely related to Saccharomyces cerevisiae, the Saccharomyces boulardii in Yomogi® is officially classified as Saccharomyces cerevisiae var boulardii Hansen CBS 5926.
Often referred to in the clinical setting as Saccharomyces boulardii or SB and SB Probiotic.
The two strains have distinct and different genetic makeup and enzyme profiles. Saccharomyces boulardii does not make a certain type of reproductive spore called an ascospore and does not use the sugar galactose. Able to grow at very high temperatures (37°C) and resistant to acid. Only Saccharomyces boulardii has proven gastrointestinal beneficial properties and effects. - Does Saccharomyces boulardii colonise the intestinal tract?
Saccharomyces boulardii does not colonise the human intestinal tract. It is a transient yeast that passes through the intestines after ingestion. S. boulardii does not attach to the mucosal cells lining the intestinal lumen, but exerts its beneficial effects on the host as it moves through the gastrointestinal tract.
- Is Saccharomyces boulardii the same as the yeast that causes yeast infections or overgrowth?
No, Saccharomyces boulardii is completely unrelated to Candida albicans and other Candida species that cause disease and overgrowth in the gastrointestinal and genitourinary tracts. Unlike Candida species that decrease the acidity of the gastrointestinal mucosal environment, ultimately making the intestinal mucosal membrane susceptible to invasion by potentially harmful bacteria and yeast. Saccharomyces boulardii exerts the opposite effect producing lactic and other acids known to inhibit potentially harmful Candida yeast species. Animal studies have shown that Saccharomyces boulardii plays a role in preventing the Candida yeast from reproducing in the gut..
- Can Yomogi® be taken together with antibiotics
Yomogi® can be taken in conjunction with antibiotics.
Unaffected by antibiotics Yomogi® may help maintain and support the gut flora during this time. - Does Yomogi® require refrigeration and is it free from, gluten, wheat or dairy products?
Yomogi® does not contain gluten or wheat products. It does however contain Lactose – 28.75mg.
Most medications containing lactose monohydrate do not have enough lactose present to affect people who are lactose intolerant, namely, those whose digestive systems do not possess the enzymes needed to digest lactose. However lactose-intolerant patients should ask their Doctor or healthcare practitioner whether or not they may safely take certain medications containing lactose.
Yomogi® does not require refrigeration. Yomogi® is lyophilized, a process of freeze drying that ensures the product is heat stable and maintains viable active cells, or colony forming units (CFU).
- Does the number of colony forming units (CFU) matter or is it the quality of the strain?
Both are correct. At product release, Yomogi® contains a minimum of 2.5 billion CFU.
Ardeypharm of Germany, the manufacturers of Yomogi®, their knowledge and experience in producing high quality probiotic strains is without question as the only E.coli strain probiotic supplier to Australia.
Yomogi is available from selected pharmacies and some healthcare practitioners.